JP2019528290A - 癌の治療のためのチオヒダントインアンドロゲン受容体アンタゴニスト - Google Patents

癌の治療のためのチオヒダントインアンドロゲン受容体アンタゴニスト Download PDF

Info

Publication number
JP2019528290A
JP2019528290A JP2019510593A JP2019510593A JP2019528290A JP 2019528290 A JP2019528290 A JP 2019528290A JP 2019510593 A JP2019510593 A JP 2019510593A JP 2019510593 A JP2019510593 A JP 2019510593A JP 2019528290 A JP2019528290 A JP 2019528290A
Authority
JP
Japan
Prior art keywords
compound
methyl
oxo
thioxo
diazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019510593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528290A5 (enExample
Inventor
ビグナン，ギルス．シー
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2019528290A publication Critical patent/JP2019528290A/ja
Publication of JP2019528290A5 publication Critical patent/JP2019528290A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019510593A 2016-08-22 2017-08-22 癌の治療のためのチオヒダントインアンドロゲン受容体アンタゴニスト Pending JP2019528290A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377932P 2016-08-22 2016-08-22
US62/377,932 2016-08-22
PCT/IB2017/055063 WO2018037342A1 (en) 2016-08-22 2017-08-22 Thiohydantoin androgen receptor antagonists for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2019528290A true JP2019528290A (ja) 2019-10-10
JP2019528290A5 JP2019528290A5 (enExample) 2020-10-01

Family

ID=60009664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510593A Pending JP2019528290A (ja) 2016-08-22 2017-08-22 癌の治療のためのチオヒダントインアンドロゲン受容体アンタゴニスト

Country Status (12)

Country Link
US (1) US20190209539A1 (enExample)
EP (1) EP3500259A1 (enExample)
JP (1) JP2019528290A (enExample)
KR (1) KR20190040030A (enExample)
CN (1) CN109640986A (enExample)
AU (1) AU2017316756A1 (enExample)
BR (1) BR112019003406A2 (enExample)
CA (1) CA3034449A1 (enExample)
MA (1) MA45992A (enExample)
MX (1) MX2019002097A (enExample)
RU (1) RU2019108092A (enExample)
WO (1) WO2018037342A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032644B (zh) * 2017-08-07 2021-08-10 正大天晴药业集团股份有限公司 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
BR112021015122A2 (pt) 2019-02-01 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Cristal de composto de diariltio-hidantoína
CN115403624B (zh) * 2022-09-30 2024-08-27 上海应用技术大学 一种二芳基硫代乙内酰脲化合物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519733A (ja) * 2010-02-16 2013-05-30 アラゴン ファーマシューティカルズ，インク． アンドロゲン受容体モジュレーターおよびその使用
WO2014066799A2 (en) * 2012-10-26 2014-05-01 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519733A (ja) * 2010-02-16 2013-05-30 アラゴン ファーマシューティカルズ，インク． アンドロゲン受容体モジュレーターおよびその使用
WO2014066799A2 (en) * 2012-10-26 2014-05-01 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor

Also Published As

Publication number Publication date
WO2018037342A1 (en) 2018-03-01
RU2019108092A (ru) 2020-09-22
US20190209539A1 (en) 2019-07-11
MA45992A (fr) 2019-06-26
MX2019002097A (es) 2019-05-15
CN109640986A (zh) 2019-04-16
KR20190040030A (ko) 2019-04-16
AU2017316756A1 (en) 2019-02-21
BR112019003406A2 (pt) 2019-05-21
CA3034449A1 (en) 2018-03-01
RU2019108092A3 (enExample) 2020-11-30
EP3500259A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
CN107286077B (zh) 一种选择性的c-kit激酶抑制剂
WO2022232320A1 (en) Small molecule inhibitors of kras g12c mutant
EP4157836A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN107428758B (zh) 丙烯酸类衍生物、其制备方法及其在医药上的用途
JP2019524711A (ja) アンドロゲン受容体アンタゴニストとしての置換ヒダントイン及びチオヒダントイン誘導体
JP2019504836A (ja) アンドロゲン受容体アンタゴニストとしての置換チオヒダントイン誘導体
CN103501610A (zh) Pi3激酶抑制剂和其用途
TW202035422A (zh) 作為ｃｄｋ抑制劑的大環化合物、其製備方法及其在醫藥上的應用
JP2019528290A (ja) 癌の治療のためのチオヒダントインアンドロゲン受容体アンタゴニスト
CN118103371A (zh) 一种egfr抑制剂及其制备方法和用途
KR20180052623A (ko) 신규 화합물
JP6609308B2 (ja) キナーゼ阻害剤としての置換マクロサイクル
JP2019524708A (ja) 癌の治療のためのチオヒダントインアンドロゲン受容体アンタゴニスト
US20240016795A1 (en) Bromodomain inhibitors for androgen receptor-driven cancers
TW202506118A (zh) 雜環炔基取代的醯胺衍生物、其製備方法及其應用
CN114555597B (zh) 异柠檬酸脱氢酶（idh）抑制剂
WO2023024545A1 (zh) Fgfr4抑制剂、组合物及其在药物制备中的用途
WO2018103663A1 (zh) 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
Sun et al. Discovery of a novel benzofuran-7-carboxamide-based PARP1/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance
CN116655600A (zh) 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途
HK1239671B (zh) 丙烯酸类衍生物、其制备方法及其在医药上的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220412